Gokula Kumar Appalanaido
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gokula Kumar Appalanaido has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Mohd Zahri Abdul Aziz
Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia
3 shared publications - Alice Zamagni
Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
2 shared publications - Arthur Sun Myint
Clatterbridge Cancer Centre, Liverpool, UK; University of Liverpool, Liverpool, UK
2 shared publications - Brigitta Gertrud Baumert
Institute of Radiation-Oncology, Cantonal Hospital Graubünden, Chur, Switzerland
2 shared publications - Francis Cho Hao Ho
Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore
2 shared publications - Hafiz Mohd Zin
Department of Biomedical Imaging, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam 13200 Kepala Batas, Pulau Pinang, Malaysia; Breast Cancer Translational Research Programme (BCTRP), Advanced Medical & Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia
2 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Springer Nature
Tongue-preserving treatment using brachytherapy and intensity-modulated radiation therapy technique for localized tongue cancer
- 13 April 2026
- Published by Springer Nature
Open AccessTongue-preserving treatment using brachytherapy and intensity-modulated radiation therapy technique for localized tongue cancer
- Open Access
- 27 February 2023
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 46 (1) , 339-352
Accuracy of a time-of-flight (ToF) imaging system for monitoring deep-inspiration breath-hold radiotherapy (DIBH-RT) for left breast cancer patients
Deep inspiration breath-hold radiotherapy (DIBH-RT) reduces cardiac dose by over 50%. However, poor breath-hold reproducibility could result in target miss which compromises the treatment success. This study aimed to benchmark the accuracy of a Time-of-Flight (ToF) imaging system for monitoring breath-hold during DIBH-RT. The accuracy of an Argos P330 3D ToF camera (Bluetechnix, Austria) was evaluated for patient setup verification and intra-fraction monitoring among 13 DIBH-RT left breast cancer patients. The ToF imaging was performed simultaneously with in-room cone beam computed tomography (CBCT) and electronic portal imaging device (EPID) imaging systems during patient setup and treatment delivery, respectively. Patient surface depths (PSD) during setup were extracted from the ToF and the CBCT images during free breathing and DIBH using MATLAB (MathWorks, Natick, MA) and the chest surface displacement were compared. The mean difference ± standard deviation, correlation coefficient, and limit of agreement between the CBCT and ToF were 2.88 ± 5.89 mm, 0.92, and − 7.36, 1.60 mm, respectively. The breath-hold stability and reproducibility were estimated using the central lung depth extracted from the EPID images during treatment and compared with the PSD from the ToF. The average correlation between ToF and EPID was − 0.84. The average intra-field reproducibility for all the fields was within 2.70 mm. The average intra-fraction reproducibility and stability were 3.74 mm, and 0.80 mm, respectively. The study demonstrated the feasibility of using ToF camera for monitoring breath-hold during DIBH-RT and shows good breath-hold reproducibility and stability during the treatment delivery.
- 27 February 2023
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 46 (1) , 339-352
Open AccessAccuracy of a time-of-flight (ToF) imaging system for monitoring deep-inspiration breath-hold radiotherapy (DIBH-RT) for left breast cancer patients
Deep inspiration breath-hold radiotherapy (DIBH-RT) reduces cardiac dose by over 50%. However, poor breath-hold reproducibility could result in target miss which compromises the treatment success. This study aimed to benchmark the accuracy of a Time-of-Flight (ToF) imaging system for monitoring breath-hold during DIBH-RT. The accuracy of an Argos P330 3D ToF camera (Bluetechnix, Austria) was evaluated for patient setup verification and intra-fraction monitoring among 13 DIBH-RT left breast cancer patients. The ToF imaging was performed simultaneously with in-room cone beam computed tomography (CBCT) and electronic portal imaging device (EPID) imaging systems during patient setup and treatment delivery, respectively. Patient surface depths (PSD) during setup were extracted from the ToF and the CBCT images during free breathing and DIBH using MATLAB (MathWorks, Natick, MA) and the chest surface displacement were compared. The mean difference ± standard deviation, correlation coefficient, and limit of agreement between the CBCT and ToF were 2.88 ± 5.89 mm, 0.92, and − 7.36, 1.60 mm, respectively. The breath-hold stability and reproducibility were estimated using the central lung depth extracted from the EPID images during treatment and compared with the PSD from the ToF. The average correlation between ToF and EPID was − 0.84. The average intra-field reproducibility for all the fields was within 2.70 mm. The average intra-fraction reproducibility and stability were 3.74 mm, and 0.80 mm, respectively. The study demonstrated the feasibility of using ToF camera for monitoring breath-hold during DIBH-RT and shows good breath-hold reproducibility and stability during the treatment delivery.
- Open Access
- 27 September 2022
- Published by Taylor & Francis in Hepatic Oncology
- Vol. 9 (3) , HEP44
Pathological complete Response with Immunotherapy and Brachytherapy to 15 Metastatic Liver Lesions in a Single Patient
Materials & methods: High dose rate interstitial brachytherapy (HDR-IBT) treatment plan for 15 metastatic liver lesions in a patient with pancreatic cancer was retrieved and analyzed for liver dose...
- 27 September 2022
- Published by Taylor & Francis in Hepatic Oncology
- Vol. 9 (3) , HEP44
Open AccessPathological complete Response with Immunotherapy and Brachytherapy to 15 Metastatic Liver Lesions in a Single Patient
Materials & methods: High dose rate interstitial brachytherapy (HDR-IBT) treatment plan for 15 metastatic liver lesions in a patient with pancreatic cancer was retrieved and analyzed for liver dose...
- Open Access
- 1 April 2022
- Published by Elsevier in Nuclear Engineering and Technology
- Vol. 54 (4) , 1414-1420
Variation of optimization techniques for high dose rate brachytherapy in cervical cancer treatment
- 1 April 2022
- Published by Elsevier in Nuclear Engineering and Technology
- Vol. 54 (4) , 1414-1420
Open AccessVariation of optimization techniques for high dose rate brachytherapy in cervical cancer treatment
- Open Access
- 30 December 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (6) , 892-898
Lateral wedge with medial only cardiac shielding (LEMONADE) technique in left chest wall adjuvant radiotherapy
Background: This dosimetric study compared lateral wedge with medial only cardiac shielding (LEMONADE) technique, for left chest wall (LCW) irradiation against three other commonly used techniques. Materials and methods: Dosimetric parameters of 22 consecutive LBC patients treated using the P1 (LEMONADE technique) were compared with 3 other virtually reconstructed plans: no cardiac shielding with paired wedges; P2 (paired wedges and medial only Y-direction shielding) and P3 (paired wedges and bilateral Y-direction shielding). Results: P1 showed better target volume (TV) coverage with the mean 90% isodose coverage of 85.59% ± 5.44 compared to 78.90% ± 8.59 and 74.22% ± 9.50 for P2 and P3, respectively. Compared to no cardiac shielding, for a 4.65% drop in TV coverage the V26Gy of heart dropped from 6.68% to a negligible 0.85% for P1. TV receiving < 30Gy is also significantly lesser for P1 compared to P2 and P3 (5.42% vs 10.64% and 15.8%), whilst there is a small difference of 2.75% between no cardiac shielding and P1. Conclusion: With the improvement in BC survival rate, cardiac toxicity associated with adjuvant irradiation for LBC is a major concern. P1 (LEMONADE) technique has a good compromise between cardiac sparing and target coverage and should suffice for most LCW irradiations. Furthermore, the LEMONADE technique is a simple, reproducible and involves fast planning for cardiac sparing, which is ideal for under-resourced departments with heavy workload. Background: This dosimetric study compared lateral wedge with medial only cardiac shielding (LEMONADE) technique, for left chest wall (LCW) irradiation against three other commonly used techniques. Materials and methods: Dosimetric parameters of 22 consecutive LBC patients treated using the P1 (LEMONADE technique) were compared with 3 other virtually reconstructed plans: no cardiac shielding with paired wedges; P2 (paired wedges and medial only Y-direction shielding) and P3 (paired wedges and bilateral Y-direction shielding). Results: P1 showed better target volume (TV) coverage with the mean 90% isodose coverage of 85.59% ± 5.44 compared to 78.90% ± 8.59 and 74.22% ± 9.50 for P2 and P3, respectively. Compared to no cardiac shielding, for a 4.65% drop in TV coverage the V26Gy of heart dropped from 6.68% to a negligible 0.85% for P1. TV receiving < 30Gy is also significantly lesser for P1 compared to P2 and P3 (5.42% vs 10.64% and 15.8%), whilst there is a small difference of 2.75% between no cardiac shielding and P1. Conclusion: With the improvement in BC survival rate, cardiac toxicity associated with adjuvant irradiation for LBC is a major concern. P1 (LEMONADE) technique has a good compromise between cardiac sparing and target coverage and should suffice for most LCW irradiations. Furthermore, the LEMONADE technique is a simple, reproducible and involves fast planning for cardiac sparing, which is ideal for under-resourced departments with heavy workload.
- 30 December 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (6) , 892-898
Open AccessLateral wedge with medial only cardiac shielding (LEMONADE) technique in left chest wall adjuvant radiotherapy
Background: This dosimetric study compared lateral wedge with medial only cardiac shielding (LEMONADE) technique, for left chest wall (LCW) irradiation against three other commonly used techniques. Materials and methods: Dosimetric parameters of 22 consecutive LBC patients treated using the P1 (LEMONADE technique) were compared with 3 other virtually reconstructed plans: no cardiac shielding with paired wedges; P2 (paired wedges and medial only Y-direction shielding) and P3 (paired wedges and bilateral Y-direction shielding). Results: P1 showed better target volume (TV) coverage with the mean 90% isodose coverage of 85.59% ± 5.44 compared to 78.90% ± 8.59 and 74.22% ± 9.50 for P2 and P3, respectively. Compared to no cardiac shielding, for a 4.65% drop in TV coverage the V26Gy of heart dropped from 6.68% to a negligible 0.85% for P1. TV receiving < 30Gy is also significantly lesser for P1 compared to P2 and P3 (5.42% vs 10.64% and 15.8%), whilst there is a small difference of 2.75% between no cardiac shielding and P1. Conclusion: With the improvement in BC survival rate, cardiac toxicity associated with adjuvant irradiation for LBC is a major concern. P1 (LEMONADE) technique has a good compromise between cardiac sparing and target coverage and should suffice for most LCW irradiations. Furthermore, the LEMONADE technique is a simple, reproducible and involves fast planning for cardiac sparing, which is ideal for under-resourced departments with heavy workload. Background: This dosimetric study compared lateral wedge with medial only cardiac shielding (LEMONADE) technique, for left chest wall (LCW) irradiation against three other commonly used techniques. Materials and methods: Dosimetric parameters of 22 consecutive LBC patients treated using the P1 (LEMONADE technique) were compared with 3 other virtually reconstructed plans: no cardiac shielding with paired wedges; P2 (paired wedges and medial only Y-direction shielding) and P3 (paired wedges and bilateral Y-direction shielding). Results: P1 showed better target volume (TV) coverage with the mean 90% isodose coverage of 85.59% ± 5.44 compared to 78.90% ± 8.59 and 74.22% ± 9.50 for P2 and P3, respectively. Compared to no cardiac shielding, for a 4.65% drop in TV coverage the V26Gy of heart dropped from 6.68% to a negligible 0.85% for P1. TV receiving < 30Gy is also significantly lesser for P1 compared to P2 and P3 (5.42% vs 10.64% and 15.8%), whilst there is a small difference of 2.75% between no cardiac shielding and P1. Conclusion: With the improvement in BC survival rate, cardiac toxicity associated with adjuvant irradiation for LBC is a major concern. P1 (LEMONADE) technique has a good compromise between cardiac sparing and target coverage and should suffice for most LCW irradiations. Furthermore, the LEMONADE technique is a simple, reproducible and involves fast planning for cardiac sparing, which is ideal for under-resourced departments with heavy workload.
- Open Access
- 1 January 2021
- Published by Fortune Journals in Archives of Clinical and Biomedical Research
- Vol. 05 (02) , 201-213
Low-Dose-Whole-Lung Radiotherapy for Older Patients with Coronavirus Disease (Covid-19) Pneumonia: A Phase I-II Prospective Non-Randomized Protocol by the International Geriatric Radiotherapy Group
Background: Coronavirus disease 19 (COVID-19) carries a high mortality rate among older patients and minorities such as ethnic Africans and Latinos. These patients suffer from chronic inflammation that may turn into a cytokine storm when infection occurs, in addition to frequently possessing multiple comorbidity factors that may also account for their higher mortality. Even though multiple organ failure results from the cytokine storm, it is pneumonia and respiratory failure that often lead to death. Low-dose-whole-lung radiotherapy (LDWLRT) may modulate the inflammatory response and decrease the need for artificial ventilation, thus improving the mortality rate. Methods: A phase I-II prospective trial, enrolling 500 patients, aged 65 years old or above from 25 countries, will be conducted to investigate the impact of LDWLRT on the mortality rate in COVID-19 patients. Selected patients will have developed viral pneumonia that does not require artificial ventilation. These patients will be followed for a year after receiving radiotherapy. The impact of the residual inflammation will be assessed using the ordinal scale. Mortality rates will also be compared among different ethnic groups and correlated with their cytokine response to the virus and number of co-morbidities. Results: Patients have been recruited in an institution in Mexico as per protocol. Patient recruitment is scheduled at another institution in Canada pending Institutional Review Board approval. The preliminary results will be used to apply for funding. Discussion and importance of the study: We postulate that LDWLRT may improve survival rates in all patients by preventing the need for artificial ventilation, which is associated with a high mortality. The differences in inflammatory response among ethnic groups prior to and following radiotherapy will serve as a valuable baseline for future prospective pandemic studies.
- 1 January 2021
- Published by Fortune Journals in Archives of Clinical and Biomedical Research
- Vol. 05 (02) , 201-213
Open AccessLow-Dose-Whole-Lung Radiotherapy for Older Patients with Coronavirus Disease (Covid-19) Pneumonia: A Phase I-II Prospective Non-Randomized Protocol by the International Geriatric Radiotherapy Group
Background: Coronavirus disease 19 (COVID-19) carries a high mortality rate among older patients and minorities such as ethnic Africans and Latinos. These patients suffer from chronic inflammation that may turn into a cytokine storm when infection occurs, in addition to frequently possessing multiple comorbidity factors that may also account for their higher mortality. Even though multiple organ failure results from the cytokine storm, it is pneumonia and respiratory failure that often lead to death. Low-dose-whole-lung radiotherapy (LDWLRT) may modulate the inflammatory response and decrease the need for artificial ventilation, thus improving the mortality rate. Methods: A phase I-II prospective trial, enrolling 500 patients, aged 65 years old or above from 25 countries, will be conducted to investigate the impact of LDWLRT on the mortality rate in COVID-19 patients. Selected patients will have developed viral pneumonia that does not require artificial ventilation. These patients will be followed for a year after receiving radiotherapy. The impact of the residual inflammation will be assessed using the ordinal scale. Mortality rates will also be compared among different ethnic groups and correlated with their cytokine response to the virus and number of co-morbidities. Results: Patients have been recruited in an institution in Mexico as per protocol. Patient recruitment is scheduled at another institution in Canada pending Institutional Review Board approval. The preliminary results will be used to apply for funding. Discussion and importance of the study: We postulate that LDWLRT may improve survival rates in all patients by preventing the need for artificial ventilation, which is associated with a high mortality. The differences in inflammatory response among ethnic groups prior to and following radiotherapy will serve as a valuable baseline for future prospective pandemic studies.
- Open Access
- 1 September 2020
- Published by OAE Publishing Inc. in Hepatoma Research
- Vol. 2020
Can radiotherapy finally “go live” in the management of liver metastases?
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
- 1 September 2020
- Published by OAE Publishing Inc. in Hepatoma Research
- Vol. 2020
Open AccessCan radiotherapy finally “go live” in the management of liver metastases?
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
- 27 May 2020
- Published by Elsevier
- p. 189-227
Radiation therapy and chemotherapy in early and advanced nasopharyngeal cancer
- 27 May 2020
- Published by Elsevier
- p. 189-227
Radiation therapy and chemotherapy in early and advanced nasopharyngeal cancer
- Open Access
- 1 January 2020
- Published by Aging and Disease in Aging and disease
- Vol. 11 (3) , 489-493
Whole-lung Low Dose Irradiation for SARS-Cov2 Induced Pneumonia in the Geriatric Population: An Old Effective Treatment for a New Disease? Recommendation of the International Geriatric Radiotherapy Group
A cytokine storm induced by SARS-Cov2 may produce pneumonitis which may be fatal for older patients with underlying lung disease. Hyper-elevation of Interleukin1 (IL-1), Tumor necrosis factor-1alfa (TNF-1 alfa), and Interleukin 6 (IL-6) produced by inflammatory macrophage M1 may damage the lung alveoli leading to severe pneumonitis, decreased oxygenation, and potential death despite artificial ventilation. Older patients may not be suitable candidates for pharmaceutical intervention targeting IL-1/6 blockade or artificial ventilation. Low dose total lung (LDTL) irradiation at a single dose of 50 cGy may stop this cytokine cascade, thus preventing, and/or reversing normal organs damage. This therapy has been proven in the past to be effective against pneumonitis of diverse etiology and could be used to prevent death of older infected patients. Thus, LDRT radiotherapy may be a cost-effective treatment for this frail patient population whom radiation -induced malignancy is not a concern because of their advanced age. This hypothesis should be tested in future prospective trials.
- 1 January 2020
- Published by Aging and Disease in Aging and disease
- Vol. 11 (3) , 489-493
Open AccessWhole-lung Low Dose Irradiation for SARS-Cov2 Induced Pneumonia in the Geriatric Population: An Old Effective Treatment for a New Disease? Recommendation of the International Geriatric Radiotherapy Group
A cytokine storm induced by SARS-Cov2 may produce pneumonitis which may be fatal for older patients with underlying lung disease. Hyper-elevation of Interleukin1 (IL-1), Tumor necrosis factor-1alfa (TNF-1 alfa), and Interleukin 6 (IL-6) produced by inflammatory macrophage M1 may damage the lung alveoli leading to severe pneumonitis, decreased oxygenation, and potential death despite artificial ventilation. Older patients may not be suitable candidates for pharmaceutical intervention targeting IL-1/6 blockade or artificial ventilation. Low dose total lung (LDTL) irradiation at a single dose of 50 cGy may stop this cytokine cascade, thus preventing, and/or reversing normal organs damage. This therapy has been proven in the past to be effective against pneumonitis of diverse etiology and could be used to prevent death of older infected patients. Thus, LDRT radiotherapy may be a cost-effective treatment for this frail patient population whom radiation -induced malignancy is not a concern because of their advanced age. This hypothesis should be tested in future prospective trials.